Long non-coding RNAs (lncRNAs) have emerged as key coordinators of biological and cellular processes. Characterizing lncRNA expression across cells and tissues is key to understanding their role in determining phenotypes including human diseases. We present here FC-R2, a comprehensive expression atlas across a broadly-defined human transcriptome, inclusive of over 109,000 coding and non-coding genes, as described in the FANTOM CAGE-Associated Transcriptome (FANTOM-CAT) study. This atlas greatly extends the gene annotation used in the original recount2 resource. We demonstrate the utility of the FC-R2 atlas by reproducing key findings from published large studies and by generating new results across normal and diseased human samples. In particular, we (a) identify tissue specific transcription profiles for distinct classes of coding and non-coding genes, (b) perform differential expression analyses across thirteen cancer types, providing new insights linking promoter and enhancer lncRNAs expression to tumor pathogenesis, and (c) confirm the prognostic value of several enhancers in cancer. Comprised of over 70,000 samples, the FC-R2 atlas will empower other researchers to investigate functions and biological roles of both known coding genes and novel lncRNAs. Most importantly, access to the FC-R2 atlas is available from https://jhubiostatistics.shinyapps.io/recount/, the recount Bioconductor package, and http://marchionnilab.org/fcr2.html.
Introduction
Long non-coding RNAs (lncRNAs) are commonly defined as transcripts devoid of open reading frames (ORFs) longer than 200 nucleotides, which are often polyadenylated. This definition is not based on their function, since lncRNAs are involved in distinct molecular processes and biological contexts not yet fully characterized 1 . Over the past few years, the importance of lncRNAs has clearly emerged, leading to an increasing focus on decoding the consequences of their modulation, studying their involvement in the regulation of key biological mechanisms during development, normal tissue and cellular homeostasis, and in disease [1] [2] [3] .
Given the emerging and previously underestimated importance of non-coding RNAs, the FANTOM consortium has initiated the systematic characterization of their biological function. Through the use of Cap Analysis of Gene Expression sequencing (CAGE-seq), combined with RNA-seq data from the public domain, the FANTOM consortium released a comprehensive atlas of the human transcriptome, encompassing more accurate transcriptional start sites (TSS) for coding and non-coding genes, including numerous novel long non-coding genes: the FANTOM CAGE Associated Transcriptome (FANTOM-CAT) 4 . We hypothesized that these lncRNAs can be measured in many RNA-seq datasets from the public domain and that they have been so far missed by the lack of a comprehensive gene annotation.
Although the systematic analysis of lncRNAs function is being addressed by the FANTOM consortium in loss of function studies, increasing the detection rate of these transcripts combining different studies is difficult because the heterogeneity of analytic methods employed. Current resources that apply uniform analytic methods to create expression summaries from public data do exist but can miss several lncRNAs because their dependency on a pre-existing gene annotation for creating the genes expression summaries 5, 6 . We recently created recount2 7 , a collection of uniformly-processed human RNA-seq data, wherein we summarized 4.4 trillion reads from over 70,000 human samples from the Sequence Reads Archive (SRA), The Figure 1 . Overview of the FANTOM-CAT/recount2 resource development. FC-R2 leverages two public resources, the FANTOM-CAT gene models and recount2. FC-R2 provides expression information for 109,873 genes, both coding (22, 110) and non-coding (87,693). This latter group encompasses enhancers, promoters, and others lncRNAs.
Validating the FANTOM-CAT/recount2 resource
We first assessed how gene expression estimates in FC-R2 compared to previous gene expression estimates from other projects.
Specifically, we considered data from the GTEx consortium (v6), spanning 9,662 samples from 551 individuals and 54 tissues types 9 . First, we computed the correlation for the GTEx data between gene expression based on the FC-R2 atlas and on GENCODE (v25) gene model in recount2, which has been already shown to be consistent with gene expression estimates from the GTEx project 7 , observing a median correlation 0.986 for the 32,922 genes in common. This result supports the notion that our pre-processing steps to disambiguate overlapping exon regions between strands did not significantly alter gene expression quantification.
Next, we assessed whether gene expression specificity, as measured in FC-R2, was maintained across tissue types. To this end, we selected and compared gene expression for known tissue-specific expression patterns, such as Keratin 1 (KRT1), Estrogen Receptor 1 (ESR1), and Neuronal Differentiation 1 (NEUROD1) ( Figure 2 ). Overall, all analyzed tissue specific 3/18 markers presented nearly identical expression profiles across GTEx tissue types between the alternative gene models considered (see Figure 2 and S1), confirming the consistency between gene expression quantification in FC-R2 and those based on GENCODE.
Figure 2.
Tissue specific expression in GTEx. Log2 expression for three tissue specific genes (KRT1, NEUROD1, and ESR1) in GTEx data stratify by tissue type using FC-R2 and GENCODE based quantification. Expression profiles are highly correlated and expressed consistently in the expected tissue types (e.g., KRT1 is most expressed in skin, NEUROD1 in brain, and ESR1 in estrogen sensitive tissue types like uterus, Fallopian tubes, and breast). Correlations are shown on top for each tissue marker. Center lines, upper/lower quartiles and Whiskers represents the median, 25/75 quartiles and 1.5 interquartile range, recpectively.
Tissue-specific expression of lncRNAs
It has been shown that, although expressed at a lower level, enhancers and promoters are not ubiquitously expressed and are more specific for different cell types than coding genes 4 . In order to verify this finding, we used GTEx data to assess expression levels and specificity profiles across samples from each of the 54 analyzed tissue types, stratified into four distinct gene categories: coding mRNA, intergenic promoter lncRNA (ip-lncRNA), divergent promoter lncRNA (dp-lncRNA), and enhancers lncRNA (e-lncRNA). Overall, we were able to confirm that these RNA classes are expressed at different levels, and that they display distinct specificity patterns across tissues, as shown for primary cell types by Hon et al. 4 , albeit with more variability 4/18 likely due to the increased cellular complexity present in tissues. Specifically, coding mRNAs were expressed at higher levels than lncRNAs (log2 median expression of 6.6 for coding mRNAs, and of 4.1, 3.8 and 3.1, for ip-lncRNA, dp-lncRNA, and e-lncRNA, respectively). In contrast, the expression of enhancers and intergenic promoters was more tissue-specific (median = 0.41 and 0.30) than what observed for divergent promoters and coding mRNAs (median = 0.13 and 0.09) ( Figure 3A ). Finally, when analyzing the percentage of genes expressed across tissues by category, we observed that coding genes are, in general, ubiquitous, while lncRNAs are more specific, with enhancers showing the lowest percentages of expressed genes (mean ranging from 88.42% to 41.98%, see Figure 3B ), in agreement with the notion that enhancer transcription is tissue specific 10 . 
Differential expression analysis of coding and non-coding genes in cancer
We analyzed coding and non-coding genes expression in cancer using TCGA data. To this end, we compared cancer to normal samples separately for 13 tumor types, using FC-R2 re-quantified data. We further identified the differentially expressed genes (DEG) in common across the distinct cancer types (see Figure 4 ). Overall, the number of DEG varied across cancer types and by gene class, with a higher number of significant coding than non-coding genes (FDR < 0.01, see table 1). Importantly, 5/18 a substantial fraction of these genes was exclusively annotated in the FANTOM-CAT, suggesting that relying on other gene models would result in missing many potential important genes (see Table 1 ). We then analyzed the consensus among cancer types. A total of 41 coding mRNAs were differentially expressed across all the 13 tumor types after global correction for multiple testing (FDR < 10 -6 , see Supplementary table S1 ). For lncRNAs, a total of 28 divergent promoters, four intergenic promoters, and three enhancers were consistently up-or down-regulated across all the 13 tumor types after global correction for multiple testing (FDR < 0.1, see Supplementary tables S2, S3, S4, respectively). dp-lncRNA e-lncRNA ip-lncRNA mRNA Supplementary Table S1 ) are associated with metabolism and oxidative stress, transcriptional regulation, cell migration and adhesion, and with modulation of DNA damage repair and apoptosis.
Three down-regulated dp-lncRNA genes, RP11-276H19, RPL34-AS1, and RAP2C-AS1, were reported to be implicated in cancer ( Supplementary Table S2 ). The first one controls epithelial-mesenchymal transition, the second is associated with
tumor size increase, while the third is associated with urothelial cancer after kidney cancer transplantation [11] [12] [13] . Among the up-regulated dp-lncRNAs ( Supplementary Table S2 ), SNHG1 has been implicated in cellular proliferation, migration and invasion of different cancer types, and to be strongly up-regulated in osteosarcoma, non-small lung cancer, and gastric cancer 14, 15 . Color coding on top of the figure indicates the RNA classes (red for mRNA, purple for dp-lncRNA, cyan ip-lncRNA, and green for e-lncRNA. These genes were select after global multiple testing correction across all 13 tumor types (see Supplementary Tables S1, S2 , S3, and S4)
Among the ip-lncRNAs ubiquitously down-regulated (see Supplementary Table S3 ), LINC00478 has been identified in many different tumors types including leukemia, breast, vulvar, prostate, and bladder cancer [16] [17] [18] [19] [20] . For instance, in vulvar squamous cell carcinoma, LINC00478 and MIR31HG expressions are correlated and associated with tumor differentiation 17 . Similarly,
LINC00478 down-regulation in ER positive breast cancer is associated with progression, recurrence, and metastasis 18 . In contrast, increased expression of SNHG17 (an ip-lncRNA, see Supplementary Table S3 ), was associated with short term survival in breast cancer, and with tumor size, stage, and lymph node metastasis in colorectal cancer 21, 22 . In addition, AC004463, another ip-lncRNA ( Supplementary Table S3 ), was found to be up-regulated in liver cancer and metastatic prostate cancer 23 .
Despite we did not identify any cancer association for common e-lncRNAs, one among those we identified, RP5-965F6, has been previously reported to be up-regulated in late-onset Alzheimer's disease 24 . Furthermore, the enhancers lncRNA class also yielded the lowest number of genes in common among all cancer types, reinforcing the concept that enhancers are expressed in a tissue specific manner (See Figure 3A and Supplementary Table S4 ).
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Finally, we focused more in depth on prostate cancer (PCa) as a prototypical example, and we were able to confirm previous findings for both coding and non-coding genes (see Supplementary Figure S2 ). For coding genes, we confirmed differential expression for known markers of PCa progression and mortality, like ERG, FOXA1, RNASEL, ARVCF, and SLC43A1 25, 26 .
Similarly, we also confirmed differential expression for non-coding genes, like PCA3, the first clinically approved lncRNA marker for PCa 27, 28 , PCAT1, a prostate-specific lncRNA involved in disease progression 29 , MALAT1, which is associated with PCa poor prognosis 30 , CDKN2B-AS1, an anti-sense lncRNA up-regulated in PCa that inhibits tumor suppressor genes activity 31, 32 , and the MIR135 host gene, which is associated with castration-resistant PCa 33 .
Enhancer expression levels hold prognostic value
The number of lncRNAs involved in cancer development and progression is rapidly increasing, we therefore analyzed the prognostic value of the lncRNAs we identified in our gene expression differential analysis in TCGA, as well as those previously reported in other studies. To this end, Chen and collaborators have recently surveyed enhancers expression in nearly 9,000 patients from TCGA 34 , using genomic coordinates from the FANTOM5 project 35 , identifying 4,803 enhancers with prognostic potential in one or more TCGA tumor types. We therefore leveraged the FC-R2 atlas to identify prognostic coding and non-coding genes using Univariate Cox proportional hazard models, comparing our results for e-lncRNAs with those reported by Chen and colleagues.
When we considered e-lncRNA expression, we identified a total of 5,382 prognostic e-lncRNAs (FDR  0.05), and no single one was associated with survival across all cancer types. Overall, the number of significant prognostic e-lncRNAs varied across tumor types, ranging from 3 in head and neck cancer to 3,850 in kidney cancers (see Supplementary Table S6 ). Notably, two (out of three) e-lncRNAs from our differential gene expression consensus list across all tumor types were also prognostic.
Higher expression of CATG00000107122 gene was associated with worse prognosis in kidney cancer (Supplementary figure   S4b ) Overall, despite differences in annotation and quantification (see Supplementary Table S5 ), we were able to confirm prognostic value for 2,765 e-lncRNAs out of the 4,803 reported by Chen et al 34 , including "enhancer 22" (ENSG00000272666), which was highlighted as a promising prognostic marker for kidney cancer (Supplementary Figure S3 ).
Finally, we analyzed the prognostic value for dp-lncRNAs, ip-lncRNAs, and mRNAs (See Supplementary Tables S7, S8, and S9, respectively), and assessed the survival prognostic potential of our consensus genes across tumor types. Thirty-seven of the 41 coding mRNAs, 22 of the 28 differentially expressed dp-lncRNAs, and two out of the four DE ip-lncRNAs, respectively, were found to be prognostic (See Supplementary Tables S10, S11, S12, and S13). Kaplan-Meier survival curves for one selected DE gene on each RNA subtype evaluated here are shown in supplementary figure S4.
Discussion
The importance of lncRNAs in cell biology and disease has clearly emerged in the past few years and different classes of lncRNAs have been shown to play crucial roles in cell regulation and homeostasis 36 . For instance, enhancers -a major category of gene regulatory elements, which has been shown to be expressed 35, 37 -play a prominent role in oncogenic processes 38, 39 
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and other human diseases 40, 41 . Despite their importance, however, there is a scarcity of large-scale datasets investigating enhancers and other lncRNA classes, in part due to the technical difficulty in applying high-throughput techniques such as ChIP-seq and Hi-C over large cohorts, and to the use of gene models that do not account for them in transcriptomics analyses.
Furthermore, the large majority of the lncRNAs that are already known -and that have been shown to be associated with some phenotype -are still lacking functional annotation.
To address these needs, the FANTOM consortium has first constructed the FANTOM-CAT meta-transcriptome, a comprehensive atlas of coding and non-coding genes with robust support from CAGE-seq data 4 In order to validate our resource, we have compared the gene expression summaries based on FANTOM-CAT gene models with previous, well-established gene expression quantifications, demonstrating virtually identical profiles across tissue types overall and for specific tissue markers. We have then confirmed that distinct classes of coding and non-coding genes differ in terms of overall expression levels and specificity patterns across cell types and tissues. Furthermore, with this approach, we were also able to identify mRNAs, promoters, enhancers, and other lncRNAs that are differentially expressed in cancer, both confirming previously reported findings, and identifying novel cancer genes exclusively annotated in the FANTOM-CAT gene model, which have been therefore missed in prior analyses with TCGA data. Finally, we also analyzed the prognostic value of the coding and non-coding genes we identified, and confirmed survival associations in TCGA for measurable enhancers.
Collectively, by confirming findings reported in previous studies, our results demonstrate that the FC-R2 gene expression atlas is a reliable and powerful resource for exploring both the coding and non-coding transcriptome, providing compelling evidence and robust support to the notion that lncRNA gene classes, including enhancers and promoters, despite not being yet fully understood, portend significant biological functions. Our resource, therefore, constitutes a suitable and promising platform for future large scales studies in cancer and other human diseases, which in turn hold the potential to reveal important cues to the understanding of their biological, physiological, and pathological roles, potentially leading to improved diagnostic and therapeutic interventions.
Finally, all results, data, and code from the FC-R2 atlas are available as a public tool. With uniformly processed expression data for over 70,000 samples and 109,873 genes ready to analyze, we want to encourage researchers to dive deeper into the study of ncRNAs, their interaction with coding and non-coding genes, and their influence on normal and disease tissues. We hope this new resource will help paving the way to develop new hypotheses that can be followed to unwind the biological role of the transcriptome as a whole.
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Methods Figure 5 . Processing the FANTOM-CAT genomic ranges. This figure summarizes the disjoining and exon disambiguation processes performed before extracting expression information from recount2 using the FANTOM-CAT gene models. A) Representation of a genomic segment containing 3 distinct, hypothetical genes: gene A having two isoforms, and genes B and C with one isoform each. Each box can be interpreted as one nucleotide along the genome. Colors indicate the 3 different genes. B) Representation of disjoint exon ranges from example in Panel A. Each feature is reduced to a set of non-overlapping genomic ranges. The disjoint genomic ranges mapping back to two or more distinct genes are removed (crossed grey boxes). After removal of ambiguous ranges, the expression information for remaining ones is extracted from recount2 and summarized at the gene level.
Data and pre-processing.
The FANTOM CAT gene catalog (permissive set) was obtained from the FANTOM consortium within the frame of the FANTOM6 project (Ramilowski J, et al., manuscript in review 42 ). This catalog accounts for 124,245 genes supported by CAGE peaks and it includes those described by Hon et al. 4 . In order to remove ambiguity due to overlapping among exons from distinct genes, the BED files containing the coordinates for all genes and exons were processed with the GenomicRanges R/Bioconductor package 44 to obtain exon coordinates disjoining. To avoid losing strand information from annotation we processed data using a two-step approach by first disjoining overlapping segments on the same strand and then across strands ( Figure 5 ). The genomic ranges (disjoint exons segments) that mapped back to more than one gene were discarded. The expression values for these ranges 10/18
were then quantified using recount.bwtool 45 (code at https://github.com/LieberInstitute/marchionni_ projects). The resulting expression quantification were processed to generate RangedSummarizedExperiment objects compatible with the recount2 framework 7, 43 (code available from https://github.com/eddieimada/fcr2).
Thus, the FC-R2 atlas provides expression information for coding and non-coding genes (including enhancers, divergent promoters, and intergenic lncRNAs) for 9,662 samples from the Genotype-Tissue Expression (GTEx) project, 11,350 samples from TCGA, and over 50,000 samples from the Sequence Read Archive (SRA).
Correlation with other studies.
To test if the pre-processing steps used for FC-R2 had a major impact on gene expression quantification, we compared our data to the published GTEx expression values obtained from recount2 (version 2, https://jhubiostatistics.
shinyapps.io/recount/). Specifically, we first compared the expression distribution of tissue specific genes across different tissue types and then computed the Pearson correlation for each gene in common across the original recount2 gene expression estimates based on GENCODE and our version based on the FANTOM-CAT transcriptome.
Expression specificity of tissue facets.
We analyzed the expression level and specificity of each gene stratified by RNA class (i.e. mRNA, e-lncRNA, dp-lncRNA, ip-lncRNA) using the same approach described by Hon et al. 4 (see Supplementary Methods) . Briefly, overall expression levels for each gene were represented by the maximum transcript per million (TPM) values observed across all samples within each tissue type in GTEx. Gene specificity was based on the empirical entropy computed using the mean expression value across tissue types. The 99.99 percent confidence intervals for the expression of each category by tissue type were calculated based on TPM values. Genes with a TPM greater than 0.01 were considered expressed.
Identification of differentially expressed genes.
We analyzed differential gene expression in 13 cancer types, comparing primary tumor with normal samples using TCGA data from the FC-R2 atlas. Gene expression summaries for each cancer type were split by RNA class (coding mRNA, intergenic promoter lncRNA, divergent promoter lncRNA, and enhancer lncRNA) and then analyzed independently. A generalized linear model approach coupled with empirical Bayes moderation of standard errors 46 was used to identify differentially expressed genes between groups. The model was adjusted for the three most relevant coefficients for data heterogeneity as estimated by surrogate variable analysis (SVA) 47 . Correction for multiple testing was performed across RNA classes by merging the resulting p-values for each cancer type and applying the Benjamini-Hochberg method 48 .
Prognostic analysis.
To evaluate the prognostic potential of the genes in FC-R2, we performed univariate Cox proportional regression analysis separately for each RNA classes (22106 mRNAs, 17,404 e-lncRNAs, 6,204 dp-lncRNAs, and 1,948 ip-lncRNAs) across each of the 13 TCGA cancer types with available survival follow-up. Genes with FDR equal or less than 0.05, using Benjamini-
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Hochberg correction 48 within the cancer type and RNA class, were deemed as significant prognostic factors. We further analyzed the prognostic value of the consensus genes we identified comparing tumors to normal samples by intersecting the corresponding gene lists with those obtained by Cox proportional regression. Finally, in order to compare the results from prognostic analyses, we obtained data on enhancers position and prognostic potential from Chen et al. original publication 34 and performed a liftover to the hg38 genome assembly to match FC-R2 coordinates.
Data Availability
All data is available from http://marchionnilab.org/fcr2.html. Expression data can be directly accessed through https://jhubiostatistics.shinyapps.io/recount/ and the recount Bioconductor package (v1.9.5 or newer)
at https://bioconductor.org/packages/recount as RangedSummarizedExperiment objects organized by The Sequence Read Archive (SRA) study ID. The data can be loaded using R-programming language and is ready to be analyzed using Bioconductor packages or the data can be exported to other formats for use in another environment.
Code Availability
All code used in this manuscript is available for reproducibility and transparency at: https://github.com/eddieimada/ fcr2 and https://github.com/LieberInstitute/marchionni_projects.
